101 related articles for article (PubMed ID: 29946909)
1. Impact of age and comorbidities on the efficacy of FC and FCR regimens in chronic lymphocytic leukemia.
Strugov V; Stadnik E; Virts Y; Andreeva T; Zaritskey A
Ann Hematol; 2018 Nov; 97(11):2153-2161. PubMed ID: 29946909
[TBL] [Abstract][Full Text] [Related]
2. Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia.
Gozzetti A; Candi V; Fabbri A; Schiattone L; Cencini E; Lauria F; Frasconi A; Crupi R; Raspadori D; Papini G; Defina M; Bartalucci G; Bocchia M
Leuk Res; 2014 Aug; 38(8):891-5. PubMed ID: 24934847
[TBL] [Abstract][Full Text] [Related]
3. First immunochemotherapy outcomes in elderly patients with CLL: a retrospective analysis.
Michallet AS; Cazin B; Bouvet E; Oberic L; Schlaifer D; Mosser L; Salles G; Coiffier B; Laurent G; Ysebaert L
J Geriatr Oncol; 2013 Apr; 4(2):141-7. PubMed ID: 24071539
[TBL] [Abstract][Full Text] [Related]
4. [Clinical efficacy and safety of chemoimmunotherapy with rituximab,fludarabine and cyclophosphamide for chronic lymphocytic leukemia].
Li F; Yi SH; Yu Z; Xing LJ; Xu Y; Qi JY; Zhao YZ; Li ZJ; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2013 May; 34(5):383-8. PubMed ID: 23688746
[TBL] [Abstract][Full Text] [Related]
5. The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab.
Panovská A; Smolej L; Lysák D; Brychtová Y; Šimkovič M; Motyčková M; Vodárek P; Lindtnerová M; Trbušek M; Malčíková J; Pospíšilová Š; Mayer J; Doubek M
Eur J Haematol; 2013 Jun; 90(6):479-85. PubMed ID: 23506191
[TBL] [Abstract][Full Text] [Related]
6. Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia.
Mato AR; Foon KA; Feldman T; Schuster SJ; Svoboda J; Chow KF; Valentinetti M; Mrkulic M; Azzollini K; Gadaleta G; Bhattacharyya PK; Zenreich J; Pascual LN; Yannotti K; Kdiry S; Howlett C; Strelec L; Porter D; Bejot C; Goy A
Am J Hematol; 2015 Jun; 90(6):487-92. PubMed ID: 25691474
[TBL] [Abstract][Full Text] [Related]
7. Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments.
Laurenti L; Innocenti I; Autore F; Vannata B; Efremov DG; Ciolli S; Del Poeta G; Mauro FR; Cortelezzi A; Borza PA; Ghio F; Mondello P; Murru R; Gozzetti A; Cariccio MR; Piccirillo N; Boncompagni R; Cantonetti M; Principe MI; Reda G; Bongarzoni V; Cervetti G; Pitini V; Foà R; Sica S; D'Arena G
Leuk Res; 2015 Oct; 39(10):1066-70. PubMed ID: 26307523
[TBL] [Abstract][Full Text] [Related]
8. Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: the French intergroup experience.
Fornecker LM; Aurran-Schleinitz T; Michallet AS; Cazin B; Guieze R; Dilhuydy MS; Zini JM; Tomowiak C; Lepretre S; Cymbalista F; Brion A; Feugier P; Delmer A; Leblond V; Ysebaert L
Am J Hematol; 2015 Jun; 90(6):511-4. PubMed ID: 25752923
[TBL] [Abstract][Full Text] [Related]
9. Persistently low lymphocyte counts after FCR therapy for chronic lymphocytic leukemia are associated with longer overall survival.
Joffe E; Ariela Arad N; Bairey O; Fineman R; Ruchlemer R; Rahimi-Levene N; Shvidel L; Greenbaum U; Aviv A; Tadmor T; Braester A; Goldschmidt N; Polliack A; Herishanu Y
Hematol Oncol; 2018 Feb; 36(1):128-135. PubMed ID: 28639416
[TBL] [Abstract][Full Text] [Related]
10. Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.
Short NJ; Keating MJ; Wierda WG; Faderl S; Ferrajoli A; Estrov Z; Smith SC; O'Brien SM
Cancer; 2015 Nov; 121(21):3869-76. PubMed ID: 26218678
[TBL] [Abstract][Full Text] [Related]
11. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
Robak T; Dmoszynska A; Solal-Céligny P; Warzocha K; Loscertales J; Catalano J; Afanasiev BV; Larratt L; Geisler CH; Montillo M; Zyuzgin I; Ganly PS; Dartigeas C; Rosta A; Maurer J; Mendila M; Saville MW; Valente N; Wenger MK; Moiseev SI
J Clin Oncol; 2010 Apr; 28(10):1756-65. PubMed ID: 20194844
[TBL] [Abstract][Full Text] [Related]
12. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia.
Foon KA; Boyiadzis M; Land SR; Marks S; Raptis A; Pietragallo L; Meisner D; Laman A; Sulecki M; Butchko A; Schaefer P; Lenzer D; Tarhini A
J Clin Oncol; 2009 Feb; 27(4):498-503. PubMed ID: 19075274
[TBL] [Abstract][Full Text] [Related]
13. Bendamustin-Rituximab Combination Is a Safe and Effective, Ambulatory Treatment for Elderly Patients with Chronic Lymphocytic Leukemia: Retrospective Real-world Analysis by Age from a German Registry and Review of the Literature.
Kleeberg UR; Linde H; Günther G; Tessen HW; Kersting M
Anticancer Res; 2016 Jun; 36(6):2827-38. PubMed ID: 27272794
[TBL] [Abstract][Full Text] [Related]
14. Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL.
Munir T; Howard DR; McParland L; Pocock C; Rawstron AC; Hockaday A; Varghese A; Hamblin M; Bloor A; Pettitt A; Fegan C; Blundell J; Gribben JG; Phillips D; Hillmen P
Leukemia; 2017 Oct; 31(10):2085-2093. PubMed ID: 28216660
[TBL] [Abstract][Full Text] [Related]
15. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.
Böttcher S; Ritgen M; Fischer K; Stilgenbauer S; Busch RM; Fingerle-Rowson G; Fink AM; Bühler A; Zenz T; Wenger MK; Mendila M; Wendtner CM; Eichhorst BF; Döhner H; Hallek MJ; Kneba M
J Clin Oncol; 2012 Mar; 30(9):980-8. PubMed ID: 22331940
[TBL] [Abstract][Full Text] [Related]
16. A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia.
Ladyzynski P; Molik M; Foltynski P
Cancer Treat Rev; 2015 Feb; 41(2):77-93. PubMed ID: 25512118
[TBL] [Abstract][Full Text] [Related]
17. Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States.
Nabhan C; Mato A; Flowers CR; Grinblatt DL; Lamanna N; Weiss MA; Davids MS; Swern AS; Bhushan S; Sullivan K; Flick ED; Kiselev P; Sharman JP
BMC Cancer; 2017 Mar; 17(1):198. PubMed ID: 28302090
[TBL] [Abstract][Full Text] [Related]
18. Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities - is there an optimal dose?
Gordon MJ; Lewis LD; Brown JR; Danilov AV
Expert Rev Hematol; 2017 Aug; 10(8):707-718. PubMed ID: 28664772
[TBL] [Abstract][Full Text] [Related]
19. Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia.
Forconi F; Fabbri A; Lenoci M; Sozzi E; Gozzetti A; Tassi M; Raspadori D; Lauria F
Hematol Oncol; 2008 Dec; 26(4):247-51. PubMed ID: 18642397
[TBL] [Abstract][Full Text] [Related]
20. A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
Willis CR; Goodrich A; Park K; Waselenko JK; Lucas M; Reese A; Diehl LF; Grever MR; Byrd JC; Flinn IW
Ann Hematol; 2006 May; 85(5):301-7. PubMed ID: 16518606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
